ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

Blood

Volumn 124, Issue 25, 2014, Pages 3738-3747

  Peirs, Sofie ^a   Matthijssens, Filip ^a   Goossens, Steven ^b   Van De Walle, Inge ^b   Ruggero, Katia ^c   De Bock, Charles E ^d   Degryse, Sandrine ^d   Canté Barrett, Kirsten ^e   Briot, Delphine ^f   Clappier, Emmanuelle ^f   Lammens, Tim ^a   De Moerloose, Barbara ^a   Benoit, Yves ^a   Poppe, Bruce ^a   Meijerink, Jules P ^e   Cools, Jan ^e   Soulier, Jean ^f   Rabbitts, Terence H ^c   Taghon, Tom ^b   Speleman, Frank ^a   Van Vlierberghe, Pieter ^a   more..

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; DOXORUBICIN; MESSENGER RNA; PROTEIN BCL 2; VENETOCLAX; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER PATIENT; CELL DIFFERENTIATION; CHILD; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; LEUKEMIA CELL; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRE T LYMPHOCYTE; THERAPY EFFECT; THYMOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; DNA MICROARRAY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IC50; JURKAT CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SURVIVAL; TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CHILD; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; JURKAT CELLS; MICE, INBRED NOD; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919701827     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-574566     Document Type: Article

References (41)

1. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med. 1994;331(19): 1253-1258.
2. Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21(19):3616-3622.
3. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3398-3406.
4. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.
5. Homminga I, Pieters R, Langerak AW, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011;19(4):484-497.
6. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106(1):274-286.
7. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-156.
8. Zuurbier L, Gutierrez A, Mullighan CG, et al. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica. 2014;99(1):94-102.
9. Inukai T, Kiyokawa N, Campana D, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol. 2012;156(3):358-365.
10. Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood. 2013;122(1): 74-82.
11. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene. 1995;11(5):853-862.
12. Bene MC, Castoldi G, Knapp W, et al; European Group for the Immunological Characterization of Leukemias (EGIL). Proposals for the of Leukemias (EGIL). Proposals for the immunological classification of acute leukemias. Leukemia. 1995;9(10):1783-1786.
13. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.
14. Niu X, Wang G, Wang Y, et al. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia. 2014;28(7):1557-1560.
15. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362-375.
16. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163(1):139-142.
17. Touzeau C, Dousset C, Le Gouill S, et al. The Bcl- 2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210-212.
18. Vaillant F, Merino D, Lee L, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24(1):120-129.
19. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2- specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013; 121(12):2285-2288.
20. BCL-2 inhibitor yields high response in CLL and SLL. BCL-2 inhibitor yields high response in CLL and SLL. Cancer Discov. 2014;4(2):OF5.
21. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011;208(4): 653-661.
22. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006; 38(5):500-501.
23. Taghon T, Waegemans E, Van de Walle I. Notch signaling during human T cell development. Curr Top Microbiol Immunol. 2012;360:75-97.
24. Anderson NM, Harrold I, Mansour MR, et al. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not moredifferentiated T-ALL cell lines. Leukemia. 2014; 28(5):1145-1148.
25. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med. 2011;208(13):2571-2579.
26. Larson RC, Fisch P, Larson TA, et al. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene. 1994;9(12): 3675-3681.
27. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008; 371(9617):1030-1043.
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
29. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324-1337.
30. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer. 2013;13(7):455-465.
31. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-681.
32. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
33. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5): 488-496.
34. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943-951.
35. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008; 111(9):4668-4680.
36. Ben Abdelali R, Roggy A, Leguay T, et al. SET-NUP214 is a recurrent gd lineage-specific fusion transcript associated with corticosteroid/ chemotherapy resistance in adult T-ALL. Blood. 2014;123(12):1860-1863.
37. McCormack MP, Young LF, Vasudevan S, et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science. 2010; 327(5967):879-883.
38. Suryani S, Carol H, Chonghaile TN, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014;20(17):4520-4531.
39. Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074-1087.
40. Ni Chonghaile T, Sarosiek KA, Vo TT, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334(6059):1129-1133.
41. Kang MH, Kang YH, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 2007;110(6):2057-2066.